Press release
Metastatic Liver Cancer Pipeline Drugs 2023 (Updated), FDA Approvals, Clinical Trials, MOA, ROA | Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., and Others
Metastatic Liver Cancer Pipeline
In the Metastatic Liver Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Metastatic Liver Cancer clinical trials studies, Metastatic Liver Cancer NDA approvals (if any), and product development activities comprising the technology, Metastatic-Liver-Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Metastatic Liver Cancer Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/report-store/metastatic-liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Metastatic Liver Cancer Pipeline Report
• DelveInsight's Metastatic Liver Cancer Pipeline analysis depicts a robust space with 20+ active players working to develop 25+ pipeline treatment therapies.
• The leading Metastatic-Liver-Cancer Companies includes Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim, and others.
• Promising Metastatic-Liver-Cancer Pipeline Therapies includes Adecatumumab, FOLFOX 4, EMD 525797, AV-299, AZD2171, Talimogene Laherparepvec, Atezolizumab, STP705, and others.
• On March 2022, AllVascular has announced drug named Intra-arterial LIOX + Capecitabine in the market by the phase 1 & 2. The treatment proposed in this trial is to administer intra-arterial chemotherapy to liver metastases from colorectal cancer when the blood flow to and from the liver has been isolated via balloon catheters through a vascular access system called the AVAS. The objective of this study is to evaluate the tumour response of repeated and isolated intra-arterial liver isolation oxaliplatin compared with the standard systemic chemotherapy (intravenous 5-FU + leucovorin + oxaliplatin [FOLFOX] or oral capecitabine with IV oxaliplatin [XELOX]).
• On November 2022, Amgen has announced drug named Talimogene Laherparepvec and Atezolizumab in the market by the phase 1. Approximately 36 DLT-evaluable subjects will be enrolled in this study. The locations of the study will be in the United States, Australia, Europe and Switzerland. The goal of this study is to evaluate the safety of intrahepatic injection (directly into the liver) of talimogene laherparepvec in combination with intravenously administered atezolizumab in subjects with triple negative breast cancer and colorectal cancer with liver metastases.
Metastatic Liver Cancer Overview
The liver is a common site for metastases from many cancer types. Cancers that spread to the liver most often are colorectal cancer as well as with breast, esophageal, stomach, pancreatic, lung, kidney and melanoma skin cancers. Cancers spread to the liver because the liver filters most of the blood from the rest of the body, and when cancer cells break away from a primary cancer, they often enter and travel through the bloodstream.
For further information, refer to the detailed Metastatic Liver Cancer Unmet Needs, click here for Metastatic Liver Cancer Ongoing Clinical Trial Analysis @ https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Metastatic Liver Cancer Emerging Drugs Profile
• exoASO STAT6: Codiak BioSciences
• STP 705: Sirnaomics
• ONCR 177: Oncorus
Metastatic Liver Cancer Pipeline Therapeutics Assessment
There are approx. 20+ Metastatic Liver Cancer companies which are developing the therapies for Metastatic-Liver-Cancer. The Metastatic Liver Cancer companies which have their Metastatic-Liver-Cancer drug candidates in the most advanced stage, i.e. phase I include, Oncorus.
Request a sample and discover the recent advances in Metastatic Liver Cancer Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Metastatic Liver Cancer Drugs and Companies
• Adecatumumab: Amgen Research (Munich) GmbH
• AZD2171: AstraZeneca
• Lipiodol: Guerbet
• DCE MRI: Bracco Diagnostics Inc
Metastatic Liver Cancer Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Metastatic Liver Cancer Therapeutics Market include-
Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim, and others.
Dive deep into rich insights for drugs for Metastatic Liver Cancer Pipeline, click here for Metastatic Liver Cancer Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Metastatic Liver Cancer Pipeline Report
• Coverage- Global
• Metastatic Liver Cancer Companies- Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim, and others.
• Metastatic Liver Cancer Therapies- Adecatumumab, FOLFOX 4, EMD 525797, AV-299, AZD2171, Talimogene Laherparepvec, Atezolizumab, STP705, and others.
• Metastatic Liver Cancer Segmentation: Product Type, Molecule Type, Route of Administration
Dive deep into rich insights for drugs for Metastatic Liver Cancer Pipeline, click here for Metastatic Liver Cancer Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Metastatic-Liver-Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic-Liver-Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ONCR 177: Oncorus
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic-Liver-Cancer Key Companies
21. Metastatic-Liver-Cancer Key Products
22. Metastatic-Liver-Cancer- Unmet Needs
23. Metastatic-Liver-Cancer- Market Drivers and Barriers
24. Metastatic-Liver-Cancer- Future Perspectives and Conclusion
25. Metastatic-Liver-Cancer Analyst Views
26. Metastatic-Liver-Cancer Key Companies
27. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/market-&-competitive-assessment
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Liver Cancer Pipeline Drugs 2023 (Updated), FDA Approvals, Clinical Trials, MOA, ROA | Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., and Others here
News-ID: 3100322 • Views: …
More Releases from DelveInsight Business Research
Von Willebrand Disease Market Insights Highlight Expanding Outlook Till 2034, De …
DelveInsight's "Von Willebrand Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Von Willebrand Disease, historical and forecasted epidemiology as well as the Von Willebrand Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Von Willebrand Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Von Willebrand Disease…
Global Artificial Kidney Market to reach USD 6.09 billion by 2032 at a CAGR of 1 …
According to DelveInsight's analysis, The growing demand for artificial kidneys is primarily fueled by the increasing prevalence of kidney failure and end-stage renal disease (ESRD), alongside a rising incidence of contributing factors such as diabetes, hypertension, and an aging global population. These trends are driving the need for advanced and efficient renal care technologies. Moreover, the expanding preference for home-based dialysis solutions, combined with continuous technological innovations and frequent product…
Global Bladder Scanners Market to grow at a CAGR of 6.12% by 2032, Evaluates Del …
According to DelveInsight's analysis, The growing prevalence of urinary disorders such as incontinence, urinary retention, and overactive bladder especially among the aging population continues to drive demand for bladder scanners. The increasing preference for non-invasive and efficient diagnostic tools is further propelling market growth, as bladder scanners provide a safe, quick, and accurate alternative to traditional catheterization. Their expanding use across hospitals, clinics, and home care settings highlights their clinical…
Global Transdermal Drug Delivery Devices Market to reach USD 121,798.76 million …
According to DelveInsight's analysis, The rising incidence of chronic diseases, along with the growing adoption of advanced third-generation transdermal drug delivery systems, is substantially driving the global market's growth.
DelveInsight's "Transdermal Drug Delivery Devices Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Transdermal Drug Delivery Devices…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
